PIP (Poly Implant Prosthese) Breast Implants - UK Test Results

Main Category: Cosmetic Medicine / Plastic Surgery
Also Included In: Breast Cancer;  Regulatory Affairs / Drug Approvals
Article Date: 06 Sep 2010 - 3:00 PDT

email to a friend   printer friendly   opinions  

The Medicines and Healthcare products Regulatory Agency (MHRA) has received encouraging results of UK testing on the silicone gel breast implants manufactured by the French company Poly Implant Prosthese (PIP).

The tests found no evidence of genotoxicity (potential for cancer) or chemical toxicity of the filler material in the implants.

The tests are not as extensive as those being carried out in France, but they have provided initial information as to whether there is a safety issue with the filler material.

MHRA Director of Devices Clinical, Dr Susanne Ludgate said, "It's reassuring that our test results have shown no evidence of any associated risks with the filler material.

"We are however waiting for the results of the French tests which are more extensive and include mechanical testing of the implant shell because there maybe a suggestion of an increased rupture rate compared with other breast implants. We will update clinicians and women once these test results are available and provide further advice on patient management as necessary.

"If women have any concerns, they should speak to their implanting surgeon.

"Implanting surgeons should report any clinical and radiological problems associated with these implants to the MHRA Adverse Incident Centre.

"Further advice and information can be obtained from the Association of Breast Surgery and the British Association of Plastic, Reconstructive and Aesthetic Surgeons (BAPRAS)."

Notes

1. As these products have been widely used in the UK, the MHRA was keen to identify as early as possible any potential toxicity associated with the implant filler. It therefore commissioned independent UK testing.

2. The previous press release about this issue can be seen on the MHRA website: Advice issued to breast implant surgeons

4. In general, a medical device cannot be marketed in the UK without carrying a CE Mark of Conformity. A CE mark is applied by the manufacturer to denote that the device meets the relevant regulatory requirements and performs as intended. For all but the very lowest risk devices, such as unmedicated bandages, an EC Certificate of Conformity must be obtained from an independent certification organisation, called a Notified Body, before the CE marking can be affixed. The MHRA is responsible for designating UK Notified Bodies and regularly audits them to ensure that they continue to perform to the required standards.

Source:
MHRA

• Additional
• References
• Citations